报价延迟最少15分钟:2026/04/03 14:43 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.47 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.64/2.41
|
|
企业价值
4.14B
|
| 资产负债 |
|
每股账面净值
-0.81
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
901.00M
|
|
每股收益
8.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film). |
